Company intelligence / Profile preview

Senesco Technologies, Inc.

New Brunswick, New Jersey, United Statessenesco.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Senesco Technologies was a clinical-stage biotech company focused on cancer therapeutics using proprietary gene regulation technology targeting the eIF5A pathway. Its lead candidate, SNS01-T, was in Phase I/II trials for multiple myeloma and other B-cell malignancies. The company merged with Fabrus in mid–2014 to combine its gene regulation approach with Fabrus’ novel monoclonal antibody discovery capabilities. Post-merger, the combined entity aimed to advance both platforms toward new oncology and immunology therapies.

Therapeutic areas: OncologyImmunology
Modalities: Gene regulation therapeutics (e.g., eIF5A modulation)Monoclonal antibodies
Industry: Biotech

Partnerships

Collaborations with large pharma/biotech companies via acquired Fabrus for therapeutic antibody discovery.

Beyond the preview

Go deeper on Senesco Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senesco Technologies, Inc..